Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 18.00p 17.50p 18.50p 18.00p 18.00p 18.00p 0.00 07:31:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 12.7 0.7 0.5 36.0 19.57

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
04/12/201621:43Omega Diagnostics1,428.00

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 18p.
Omega Dia has a 4 week average price of 17.41p and a 12 week average price of 17.23p.
The 1 year high share price is 20.75p while the 1 year low share price is currently 13.63p.
There are currently 108,745,669 shares in issue and the average daily traded volume is 51,504 shares. The market capitalisation of Omega Dia is £19,574,220.42.
longshanks: And don't forget they all have "shareholder friendly" options that only vest once the share price reaches 50p.It looks to me like we are reaching a prime price point. Selling into the last "surge" has so far failed to defeat the rise and whilst I'm looking for 20p as the first sign that we are starting a bull run, I am confident the upside now is far ahead of any downside risk.
rivaldo: Encouraging comments here from the FD and MD (Andrew Shepherd). I wonder what the share price will be once the market latches on to the possibility of $115m of revenues from CD4 kits. Just a fraction of that would do wonders for a small cap like ODX.... Http:// Extract: "Kieron Harbinson finance director: “It’s clearly early days; there needs to be an engagement programme with IDS. We will examine all options, but the fact they have made an approach tells us they recognise the value of the asset we’ve created over the past five years. Until there is clarification we will continue to develop the range of tests.” In October Omega CE-Marked its allergy launch panel, comprising 41 allergens which are capable of being run on IDS’ iSYS instrument. There are plans to grow this number to 120 – for which it received a £1.8m grant from Scottish Enterprise in August. The company has also made “significant progress” with its Visitect CD4 product. After lengthy delays, the tool for determining in the field whether HIV patients require retroviral drug treatment, has now been tested in more than 500 patients in three UK hospitals. Production will now commence on 10,000 devices for external field trials in India, France and sub-Saharan Africa. “A lot of data is going to come from these studies in the first calendar quarter,” said Mr Shepherd. “It takes some time to verify all that data so we’re expecting at the moment we’ll be launching the product with a CE-Marking in the second half of calendar 2017.” The World Health Organisation has estimated that around 22 to 23 million CD4 kits could be required per year, retailing at $5. “There is a significant market out there and everyone we speak to in this global health arena is saying we need this product, we need it desperately, right down at field level,” said Mr Shepherd. The company’s allergy and autoimmune division saw sales grow 11 per cent to £1.76m, while its infectious disease division grew sales by one per cent to £1.23m. In this area its Pune site in India is now producing Malaria point of care kits, which Mr Shepherd said would drive growth in that division. “We’ve invested £1m in Pune and it’s now time for that to start generating a commercial return,” said Mr Harbison. “Malaria will be first but we’ve got a pipeline of future products to come of that facility.” Its food intolerance division grew 15 per cent to £3.84m, driven by ongoing success in the US. Omega also noted growth in Middle East and India, where sales grew 46 per cent. "
rivaldo: Nice reminder barrywhit. We know from the update that the results will be good, so we may well see a move upwards in the share price in reaction. Hopefully there will be more news on CD4 and Allersys, though there was a pretty full update on 17th October, so I'm not sure there'll be much more to say since then.
rivaldo: Nice start to the week - anything up (apart from the share price!)?
p1nkfish: Perhaps they don't want the attention yet until potential jumps over to results. If so I very much respect that and it can be a sign of confidence. They know they don't have to manage the share price and it will take care of itself in time and be based on genuine strong fundamentals, not just potential and hope. No need to attract speculators.
shanklin: ...Still if the OMX share price went up 5.7% per day every day I could change my mind on this :-)
hyperboreus: Increase in headcount regarding Allersys and growth in Food Intolerance business will inevitably affect profits despite the increase in sales for this year. Any positive news regarding Visitect field trials might give the share price a boost but unless something 'unexpected' occurs, good or bad, I reckon Omega is fairly valued at these levels for the time being as commercial revenues from Visitect are not likely until some time in 2018 assuming all goes well.
barrywhit: Good to see the increase in share price given they are reasonably small trades......
gary38: Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy
hyperboreus: There were two large trades yesterday, the above comment regarding Oryx being just one of them, it will be interesting to see who the other trade relates to. The share price responded positively yesterday and likewise today but interesting to note that is still below the 17p placing in May 2013 that raised £4 million. I think that Oryx have timed their purchase perfectly, for what it is worth I have recently tripled my original holding that I have held since 2012 taking full advantage of a share price around 14p
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161205 02:19:38